BMVC is a potent G-quadruplex (G4) stabilizer and selective telomerase inhibitor (antagonist) with IC50 of about 0.2 μM. BMVC inhibits Taq DNA polymerase with IC50 of about 2.5 μM. BMVC increases the melting temperature of the telomere G4 structure and accelerates the shortening of telomere length. anti-cancer effect.

Physicochemical Properties

Molecular Formula	C28H25I2N3
Molecular Weight	657.327151060104
Exact Mass	657.013
CAS #	627810-06-4
PubChem CID	11399607
Appearance	Orange to red solid powder
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	4
Heavy Atom Count	33
Complexity	572
Defined Atom Stereocenter Count	0
SMILES	[I-].[I-].N1C2C=CC(/C=C/C3C=C[N+](C)=CC=3)=CC=2C2C=C(/C=C/C3C=C[N+](C)=CC=3)C=CC1=2
InChi Key	FKOQWAUFKGFWLH-UHFFFAOYSA-M
InChi Code	InChI=1S/C28H24N3.2HI/c1-30-15-11-21(12-16-30)3-5-23-7-9-27-25(19-23)26-20-24(8-10-28(26)29-27)6-4-22-13-17-31(2)18-14-22;;/h3-20H,1-2H3;2*1H/q+1;;/p-1
Chemical Name	3,6-bis[(E)-2-(1-methylpyridin-1-ium-4-yl)ethenyl]-9H-carbazole;diiodide
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	The proportion of sub-G1 phase cells was considerably increased after 18 days of treatment with BMVC (0.5 μM; 0-18 days; H1299 cells) [1]. When H1299 cells are treated with 0.5 μM BMVC for 0–18 days, their growth is stopped, and eventually, they undergo apoptosis. H1299 cell senescence program is induced by long-term BMVC therapy [1]. BMVC-treated cancer cells exhibited morphological alterations, decreased bromodeoxyuridine incorporation, and β-galactosidase activity, which are hallmarks of senescence. Progressive telomere shortening and the discovery of DNA damage foci accompany the senescent phenotype caused by BMVC, suggesting that telomere decapping may result from BMVC after prolonged treatment [1]. Additionally, colony-forming potential, anchorage-independent proliferation, and cell migration are among the tumor-related characteristics of cancer cells that BMVC suppresses [1].
ln Vivo	The administration of BMVC (1 mg/kg; intraperitoneally; every 3 days) to BALB/cAnN.Cg-Foxn1nu/CrlNarl mice attenuates the in vivo carcinogenic potential of cancer cells [1].
Cell Assay	Cell cycle analysis [1] Cell Types: H1299 cells Tested Concentrations: 0.5 μM Incubation Duration: 0 days, 6 days, 12 days, 18 days Experimental Results: The percentage of sub-G1 phase cells increased Dramatically after 18 days. Apoptosis analysis [1] Cell Types: H1299 Cell Tested Concentrations: 0.5 μM Incubation Duration: 0 days, 6 days, 12 days, 18 days Experimental Results: Increased apoptotic cells.
Animal Protocol	Animal/Disease Models: BALB/cAnN.Cg-Foxn1nu/CrlNarl mice injected with H1299 cells [1] Doses: 1 mg/kg Route of Administration: intraperitoneal (ip) injection; once every 3 days Experimental Results: The growth rate of tumors in the animals was Dramatically slower than that of the control animal. The mouse tumor cells indeed entered a state of apoptosis.
References	[1]. G-quadruplex stabilizer 3,6-bis(1-methyl-4-vinylpyridinium)carbazole diiodide induces accelerated senescence and inhibits tumorigenic properties in cancer cells. Mol Cancer Res. 2008 Jun;6(6):955-64. [2]. A Novel Method for Screening G-quadruplex Stabilizers to Human Telomeres. Journal of the Chinese Chemical Society, 2011, 58, 296-300.

Solubility Data

Solubility (In Vitro)

DMSO : ~10 mg/mL (~15.21 mM)

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	1.5213 mL	7.6065 mL	15.2131 mL
	5 mM	0.3043 mL	1.5213 mL	3.0426 mL
	10 mM	0.1521 mL	0.7607 mL	1.5213 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.